Australasian Gastrointestinal Pathology Society (AGPS) consensus guidelines for universal defective mismatch repair testing in colorectal carcinoma.

[1]  Ya-nan Zhang,et al.  The Prognostic Value of Deficient Mismatch Repair in Stage II–IVa Nasopharyngeal Carcinoma in the Era of IMRT , 2020, Scientific Reports.

[2]  P. Dunne,et al.  Punctate MLH1 mismatch repair immunostaining in colorectal cancer , 2019, Histopathology.

[3]  Aung Ko Win,et al.  Cancer Risks for PMS2-Associated Lynch Syndrome. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  C. Gilks,et al.  Artefactual punctate MLH1 staining can lead to erroneous reporting of isolated PMS2 loss , 2018, Histopathology.

[5]  W. Frankel,et al.  Two-stain immunohistochemical screening for Lynch syndrome in colorectal cancer may fail to detect mismatch repair deficiency , 2018, Modern Pathology.

[6]  O. Basturk,et al.  Immunohistochemical null-phenotype for mismatch repair proteins in colonic carcinoma associated with concurrent MLH1 hypermethylation and MSH2 somatic mutations , 2018, Familial Cancer.

[7]  C. Rosty,et al.  Yield of Universal Testing for DNA Mismatch Repair Protein Deficiency in Colorectal Carcinoma From an Australian Community-based Practice , 2018, bioRxiv.

[8]  A. Gill,et al.  Real world experience of BRAFV600E mutation specific immunohistochemistry in colorectal carcinoma. , 2018, Pathology.

[9]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[10]  P. Møller,et al.  Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database , 2017, Gut.

[11]  M. Ladanyi,et al.  Universal screening for microsatellite instability in colorectal cancer in the clinical genomics era: new recommendations, methods, and considerations , 2017, Familial Cancer.

[12]  M. Jenkins,et al.  Costs and outcomes of Lynch syndrome screening in the Australian colorectal cancer population , 2018, Journal of gastroenterology and hepatology.

[13]  W. Frankel,et al.  Molecular genetics of microsatellite-unstable colorectal cancer for pathologists , 2017, Diagnostic Pathology.

[14]  A. Mattia,et al.  A tailored approach to BRAF and MLH1 methylation testing in a universal screening program for Lynch syndrome , 2017, Modern Pathology.

[15]  Aung Ko Win,et al.  Tumor testing to identify lynch syndrome in two Australian colorectal cancer cohorts , 2017, Journal of gastroenterology and hepatology.

[16]  E. Steyerberg,et al.  Cost-effectiveness of routine screening for Lynch syndrome in endometrial cancer patients up to 70years of age. , 2016, Gynecologic oncology.

[17]  R. Pai,et al.  A Practical Approach to the Evaluation of Gastrointestinal Tract Carcinomas for Lynch Syndrome , 2016, The American journal of surgical pathology.

[18]  E. Kuipers,et al.  Cost-effectiveness of routine screening for Lynch syndrome in colorectal cancer patients up to 70 years of age , 2016, Genetics in Medicine.

[19]  P. Devilee,et al.  Combined mismatch repair and POLE/POLD1 defects explain unresolved suspected Lynch syndrome cancers , 2015, European Journal of Human Genetics.

[20]  P. Møller,et al.  Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database , 2015, Gut.

[21]  F. Gao,et al.  Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  B. Leggett,et al.  Clinicopathological and molecular features of sessile serrated adenomas with dysplasia or carcinoma , 2015, Gut.

[23]  A. Rashid,et al.  Assessment of BRAF V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing , 2015, Molecular Cancer Therapeutics.

[24]  A. Barkun,et al.  American Gastroenterological Association Technical Review on the Diagnosis and Management of Lynch Syndrome. , 2015, Gastroenterology.

[25]  F. Gao,et al.  Impact of an immunohistochemistry-based universal screening protocol for Lynch syndrome in endometrial cancer on genetic counseling and testing. , 2015, Gynecologic oncology.

[26]  M. Kattan,et al.  Comparative effectiveness of screening strategies for Lynch syndrome. , 2015, Journal of the National Cancer Institute.

[27]  S. Gruber,et al.  Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  H. Mackay,et al.  Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing , 2014, Cancer.

[29]  W. Frankel,et al.  Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations. , 2014, Gastroenterology.

[30]  Y. Niv,et al.  How reliable is immunohistochemical staining for DNA mismatch repair proteins performed after neoadjuvant chemoradiation? , 2014, Human pathology.

[31]  Markku Miettinen,et al.  Detection of the BRAF V600E Mutation in Colon Carcinoma: Critical Evaluation of the Imunohistochemical Approach , 2014, The American journal of surgical pathology.

[32]  J. Church,et al.  Guidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer , 2014, The American Journal of Gastroenterology.

[33]  A. Bojesen,et al.  Heterogenous mismatch-repair status in colorectal cancer , 2014, Diagnostic Pathology.

[34]  V. Georgoulias,et al.  Prognostic and predictive significance of MSI in stages II/III colon cancer. , 2014, World journal of gastroenterology.

[35]  A. Chou,et al.  BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer , 2013, Modern Pathology.

[36]  Aung Ko Win,et al.  BRAFV600E Immunohistochemistry Facilitates Universal Screening of Colorectal Cancers for Lynch Syndrome , 2013, The American journal of surgical pathology.

[37]  J. Hornick,et al.  Immunohistochemistry using the BRAF V600E mutation‐specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma , 2013, Histopathology.

[38]  R. Ward,et al.  Population-based molecular screening for Lynch syndrome: implications for personalized medicine. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  P. Møller,et al.  Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts , 2013, Gut.

[40]  J. Potter,et al.  Identification of Lynch syndrome among patients with colorectal cancer. , 2012, JAMA.

[41]  A. Spurdle,et al.  Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification , 2012, Journal of Medical Genetics.

[42]  Marc S. Williams,et al.  Lynch syndrome screening implementation: business analysis by a healthcare system. , 2011, The American journal of managed care.

[43]  C. Boland,et al.  Strategies to Identify the Lynch Syndrome Among Patients With Colorectal Cancer , 2011, Annals of Internal Medicine.

[44]  M. Kloor,et al.  Biallelic MLH1 SNP cDNA expression or constitutional promoter methylation can hide genomic rearrangements causing Lynch syndrome , 2011, Journal of Medical Genetics.

[45]  H. Zentgraf,et al.  Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody , 2011, Acta Neuropathologica.

[46]  Michael S. Rentz,et al.  Immunohistochemical Staining for DNA Mismatch Repair Proteins in Intestinal Tract Carcinoma: How Reliable are Biopsy Samples? , 2011, The American journal of surgical pathology.

[47]  R. Yantiss,et al.  Neoadjuvant Therapy Induces Loss of MSH6 Expression in Colorectal Carcinoma , 2010, The American journal of surgical pathology.

[48]  A. Gill,et al.  Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma , 2010, Pathology.

[49]  A. Bateman,et al.  DNA mismatch repair enzyme immunohistochemistry in colorectal cancer: a comparison of biopsy and resection material , 2010, Pathology.

[50]  R. Labianca,et al.  Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  C. Boland,et al.  Report from the Jerusalem workshop on Lynch syndrome-hereditary nonpolyposis colorectal cancer. , 2010, Gastroenterology.

[52]  Heather Hampel,et al.  The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer , 2010, Genetics in Medicine.

[53]  Laura H. Tang,et al.  Immunohistochemistry as First-line Screening for Detecting Colorectal Cancer Patients at Risk for Hereditary Nonpolyposis Colorectal Cancer Syndrome: A 2-antibody Panel May be as Predictive as a 4-antibody Panel , 2009, The American journal of surgical pathology.

[54]  Jukka-Pekka Mecklin,et al.  Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  Heather Hampel,et al.  Feasibility of screening for Lynch syndrome among patients with colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  G. Parmigiani,et al.  Whole pelvic helical tomotherapy for locally advanced cervical cancer: technical implementation of IMRT with helical tomothearapy , 2009, Radiation oncology.

[57]  R. Houlston,et al.  Systematic review of microsatellite instability and colorectal cancer prognosis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  J. Mecklin,et al.  The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC) , 1991, Diseases of the colon and rectum.

[59]  M. Ladanyi,et al.  Secondary mutation in a coding mononucleotide tract in MSH6 causes loss of immunoexpression of MSH6 in colorectal carcinomas with MLH1/PMS2 deficiency , 2013, Modern Pathology.

[60]  Ewout W Steyerberg,et al.  The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. , 2011, Gastroenterology.

[61]  Suet Yi Leung,et al.  Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1 , 2009, Nature Genetics.

[62]  Randall W Burt,et al.  ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes , 2015, The American Journal of Gastroenterology.

[63]  Jeffrey R. Botkin,et al.  Summary of Recommendations: The Evaluation of Genomic Applications , 2022 .